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Discussion on the use of taxanes for treatment of breast cancers 
in BRCA1 mutations carriers
Pavel Elsakov
Vilnius University, Institute of Oncology, Lithuania
BRCA1-associated cancers differ from non-here-
ditary cancers for many factors, including somatic
mutation. It can be a subject of discussion that 
the natural history and response to treatment also
may differ between the hereditary and sporadic
subgroups. Three frequent BRCA1 mutations
(5382insC, 4153delA, C61G) in the Baltic countries
(Lithuania, Latvia, Byelorussia and Poland) open 
a way for the chip test to select a subgroup from
women with breast cancer. These women with BRCA1
breast cancer have a chance to get adequate
treatment, including neo-adjuvant chemotherapy. So
far many retrospective studies of survival, that used
the same gold standard treatment for women with
BRCA1 breast cancer and for women without 
a mutation, have not found a difference between
these groups. Some studies show a worse survival
result in women with a BRCA1 mutation than women
without the mutation.
Byrski et al. in the article Response to neo-
adjuvant chemotherapy in women with BRCA1
positive breast cancer confirm that use of taxane in
neo-adjuvant chemotherapy is not effective for
treatment in women with positive BRCA1 breast
cancer.
Independently, on a small number of studied
patients, the results and conclusions of the study
make it possible to form the opinion that it is really
necessary to change the view on combination of
chemotherapy (including neo-adjuvant) with other
treatment methods of women with BRCA1 positive
breast cancer. Another conclusion: there is no
difference in response between negative oestrogen
receptor (ER) and positive ER to taxane neo-adjuvant
chemotherapy. So we need to develop a strategy of
hereditary cancer identification by BRCA1 mutation
testing only after that to consider using taxane in
neo-adjuvant chemotherapy.
Lenka Foretova
Department of Cancer Epidemiology and Genetics, Masaryk
Memorial Cancer Institute, Brno, Czech Republic
These results are very interesting and important. In
the Czech Republic (CR), we have a large series of
women with breast cancer tested for BRCA1 and
BRCA2 mutations. The situation with genetic testing is
more complicated in the CR since the germline
mutations are scattered through the whole BRCA1 or
BRCA2 gene and complete testing of both genes is
required. We have not done any analysis of
retrospective data on neo-adjuvant chemotherapy in
BRCA1 carriers with breast cancer in our cohort of
tested patients yet, and thus we cannot discuss your
results. But my suggestion is to get together a large
retrospective study of all BRCA1 positive breast cancer
patients within Europe (or elsewhere) and have really
very conclusive results. The data are available in each
centre and a large multinational study should not be
a big problem.
Your suggestion of having all breast cancer
patients tested for BRCA1 mutations before
chemotherapy is unrealistic in the Czech Republic.
The testing requires rather complicated analysis of
the whole gene and the insurance would not pay for
it. So far we have tested women with breast cancer
if they fulfil our testing criteria, sporadic breast cancer
diagnosed below 35, bilateral sporadic breast cancer
diagnosed below 50 and familial forms of
breast/ovarian cancer. The time needed for the
testing is quite long so women do not have the results
before chemotherapy is started.
The most frequently used chemotherapy regimen
for breast cancer in Masaryk Memorial Cancer Institute
in Brno, Czech Republic, is based on anthracyclines.
In some high-risk cases taxanes are used in
combination with anthracyclines. Taxanes are mostly
used for relapses when BRCA1 results are already
available in indicated cases.
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For the differentiation of the chemotherapy
according to the BRCA1 status we suggest replicating
your results in a large multicentre case/control study.
We are ready to join it.
Petr Goetz
Institute of Biology and Medical Genetics of 2nd Medical School
and of University Hospital Motol, Charles University Prague,
Czech Republic, e-mail: petr.goetz@lfmotol.cuni.cz
Opinion of editorial board member
The data presented in Bryski et al.’s paper Response
to neo-adjuvant chemotherapy in women with 
BRCA1-positive breast cancer seem to be interesting
and probably promising for effective breast cancer
therapy. The authors concluded that BRCA1 carriers of
three BRCA1 founder mutations in Poland are less
sensitive to docetaxel in neoadjuvant therapy in
comparison with BRCA1 normal controls. Presented
data match previous results on cell lines. A few clinical
studies are not quite unequivocal. In the study tumour
size was determined in all patients, also by
mammography, which is questionable in BRCA1
mutation carriers having in mind the role of BRCA1
protein in repair processes.
The course of various types of breast cancers and
the sensitivity to the different therapeutic procedures
depends on individually heterogeneous number of
expressed genes, which complicates such type of studies.
Anyway, the presented results of the Polish population
should motivate an international multicentric study to get
more reliable, possibly population-dependent results.
Clinical impact and authors’ recommendation of
BRCA1 testing in each woman with a newly diagnosed
breast cancer and modification of neo-adjuvant
chemotherapy associated with that is appropriate for 
a well organized system of breast cancer management
as it is in Poland. It will also represent the continuation of
the study and getting more numerous samples of patients.
Johannes W.B. de Groot1, 
Winette T.A. van der Graaf2
1Department of Internal Medicine, Isala Klinieken Zwolle, 
the Netherlands, e-mail: j.w.b.de.groot@isala.nl
2Department of Medical Oncology, Radboud University
Nijmegen Medical Centre, Nijmegen, the Netherlands
BRCA1 and treatment decisions in breast cancer
The focus of attention after surgical resection of
breast cancer is to establish which patients will gain
benefit from adjuvant therapies such as chemotherapy,
hormonal treatment, targeted therapy and radiotherapy.
Presently, treatment decisions are made based on the
age and menopausal status of the patient and
histopathological features of the tumour. Molecular
markers currently used to predict treatment response
include oestrogen receptor (ER)-α, progesterone
receptor (PgR), and the epidermal growth factor
receptor HER2/neu. The current strategy aimed at
improving the outcome of breast cancer patients is
mainly based on the identification of additional
biomarkers that could help in the prediction of response
to specific systemic anti-tumour therapy.
There is no clear agreement on the importance of
individual molecular markers or their clinically relevant
levels. Recent studies demonstrated that the genetic
makeup or gene-expression profile of a tumour is a strong
determinant of its susceptibility to develop distant
metastases [1, 2]. Classification of patients into high-risk
and low-risk subgroups on the basis of a gene-expression
profile may be a useful means of guiding adjuvant
therapy in patients with breast cancer. Several prospective,
randomised studies such as the MINDACT (Microarray
In Node negative Disease may Avoid ChemoTherapy)
trial (EORTC Protocol 10041-BIG 3-04) that compare
such gene-expression signatures with a common clinical-
pathological prognostic tool in selecting patients for
adjuvant chemotherapy are underway.
In addition, the tumour suppressor gene BRCA1
might be promising as a predictive biomarker. However,
the question remains whether there are sufficient
compelling data to add routine BRCA1 testing into
clinical practice to tailor current chemotherapy
regimens in such a way that maximum benefit is gained
with minimal exposure to unnecessary drugs.
To answer this question, it is necessary to establish
whether the presence of a germline BRCA1 mutation or
reduced BRCA1 expression levels actually affects the
prognosis of patients with breast cancer. It is estimated
that 5-10% of all breast cancer cases are hereditary,
and BRCA1 and BRCA2 have been identified as being
accountable for 21-40% of these cases [3, 4]. Somatic
BRCA1 mutations are hardly ever observed in sporadic
breast tumours; however, up to 30% of cases have
abridged expression of BRCA1 mRNA and protein due
to epigenetic silencing of the BRCA1 gene [5-7].
Breast cancers in patients with BRCA1 mutations
mostly occur in younger women, and such tumours are
often poorly differentiated, have a basal-like phenotype
characterised by the expression of basal epithelial
markers such as CK5 and CK14, and lack ER, PgR and
HER2/neu receptors. Furthermore, TP53 mutations
occur frequently in BRCA1-mutated tumours [8]. These
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features may suggest that hereditary breast cancer has
an unfavourable outcome. However, a randomised or
prospective study between patients with sporadic breast
cancer and BRCA1 mutation carriers with breast cancer
to investigate the prognostic value of BRCA1 is yet to
be performed. In addition, the studies that have
addressed the prognostic impact of germline BRCA1
mutations [reviewed in reference 9] vary with respect
to different confounding factors such as numbers of
patients, selecting and testing of cases and control
groups, applied therapy, ethnic background or specific
mutations. Consequently, no definitive conclusions can
be drawn about the prognosis of breast cancer patients
with germline BRCA1 mutations in relation to sporadic
breast cancers with or without epigenetic silencing of
BRCA1. Until now, except for increased risk of
contralateral breast cancer, the presence of a BRCA1
mutation does not seem to offer supplementary
prognostic information to ER, PgR, and HER2/neu [9,
10]. Furthermore, it is unclear as to whether sporadic
tumours with reduced expression of BRCA1 behave just
as BRCA1-mutant tumours.
Although the prognostic value of BRCA1 remains
to be determined, BRCA1 status may influence the
response to chemotherapy. It is evident that BRCA1 can
regulate differential sensitivity to diverse classes of
cytostatic agents in vitro. The absence of BRCA1 may
result in increased sensitivity to DNA damage-based
chemotherapy, whereas the presence of BRCA1
endorses an increase in sensitivity to antimicrotubule
agents [11]. Initial indications that BRCA1 may predict
response to chemotherapy were obtained from several
small retrospective studies that evaluated response to
neoadjuvant anthracycline-based regimens. These
studies suggested that BRCA1-mutant tumours were
highly sensitive to anthracycline-based chemotherapy
and that patients with BRCA1-related breast cancer
gained more benefit from chemotherapy than patients
that were non-carriers [12, 13]. However, a recent,
fairly large, Israeli study with comparatively
homogeneous treatment regimens that were chosen
without knowledge of mutational status found that
influence of a BRCA1 mutation on the outcome of DNA
damage-based chemotherapy was not statistically
significant [10]. Therefore, the clinical evidence to date
suggests that the additional benefit from DNA damage-
based chemotherapy for patients with BRCA1 germline
mutations compared to non-carriers is, at best, limited.
In sporadic breast cancer cases, there is conflicting
evidence as to whether tumours with epigenetic
inactivation of BRCA1 will gain benefit to DNA damage-
based chemotherapy. To date, studies examining reduced
BRCA1 mRNA levels in sporadic breast cancer and its
role in chemotherapy response have shown results that
contradict preclinical data [11]. In one specific study,
only 32% of tumours with low BRCA1 mRNA levels were
found to respond to DNA damage-based chemotherapy
compared with a 65% response rate in tumours with high
levels of BRCA1 mRNA [14].
There have been only a small number of studies
examining BRCA1 in response to taxane-based
chemotherapy in breast cancer. A recent multi-centre
study from Poland evaluated response to neo-adjuvant
chemotherapy in 44 women with BRCA1-positive invasive
breast cancer matched to 41 BRCA1-negative controls.
BRCA1 carriers were less likely to respond to neoadjuvant
docetaxel in combination with doxorubicin than 
non-carriers [15]. In contrast, a study in 25 Japanese
women with advanced breast cancer reported that low
levels of BRCA1 tended toward increased sensitivity to
neoadjuvant docetaxel, but this did not reach statistical
significance [16]. However, both studies involved relatively
few patients and neoadjuvant non-standardised treatment
protocols. Furthermore, to predict response to docetaxel,
various other biological parameters related to: 
(1) efflux (p-glycoprotein) and metabolism (CYP3A4); 
(2) beta-tubulin (somatic mutation of beta-tubulin and
changes in levels of beta-tubulin isotypes); (3) cell cycle
(HER2 and Aurora-A); and (4) apoptosis (TP53, BCL2
and thioredoxin) have to be taken into account [17].
It is also important to bear in mind that known
susceptibility genes account for less than 25% of the
familial risk of breast cancer, and the residual genetic
variance is likely to be due to variants conferring more
moderate risks [18]. In all likelihood, BRCA1 is not the
only breast cancer susceptibility gene. Recently five
novel breast cancer susceptibility loci were identified,
and this study demonstrated conclusively that some of
the variation in breast cancer risk is due to common
alleles [19]. Especially due to the infrequent occurrence
of BRCA1 mutations, it would not seem reasonable or
economically feasible to test every woman with breast
cancer for either mutations in BRCA1 or expression of
the protein in the tumour.
In conclusion, there is currently no place for routinely
testing every new breast cancer for germline mutations
in BRCA1 or BRCA1 expression in the tumour.
Furthermore, until results of prospectively executed studies
appear that underscore the importance of BRCA1
status, the present data are insufficient to support 
a BRCA1-based policy when assigning adjuvant treatment.
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This observational study provides important clues
about treatment options of BRCA1 carriers and
sporadic basal-like breast cancers. There is an urgent
need to search for treatment alternatives for patients
who have ’’triple negative’’ breast tumours, as currently
this group of patients is without the advantages of
traditional or recently developed targeted therapies.
The majority of ‘‘triple negative’’ breast tumours are
basal-like cancers that have inactivated BRCA1
function, and chemotherapy is usually the only
treatment option for them. So, it is important and
practical first to test the sensitivity of available agents
while trying to develop new drugs that are especially
effective for basal-like cancers.
As mentioned in the report by Byrski et al. (Br Can
Res Treat 2007), one more problem is whether there are
different subgroups with different treatment responses in
basal-like cancer, such as cases with BRCA1 mutation or
cases with both basaloid and myoepithelial differentiation.
Another problem is to develop testing methods to select
patients who are sensitive to different therapies. The
simplest widely available method is immunohisto-
chemistry. There are some recently published studies
showing that immunohistochemical panels are useful to
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determine basaloid differentiation of breast tumours. It
is also important to find out whether there is a difference
in response to the treatments between patients with
inactivated BRCA1 function without or with BRCA1
mutation. The study of Byrski et al. shows that taxane-
based neoadjuvant treatment is ineffective for BRCA1
carriers. Interestingly, the specific BRCA1 mutation did
not seem to be the determining factor in response to
docetaxel neo-adjuvant therapy, since individual patients
with the same mutation could be responders or 
non-responders. It will be important to extend this study
to a large group of sporadic basaloid breast tumours to
understand whether they also have similar features.
Neva E. Haites
The University Court of the University of Aberdeen,
Department of Medicine, Foresterhill, United Kingdom, 
e-mail: n.haites@abdn.ac.uk 
Many thanks for letting me see this paper. It looks
very interesting and potentially important. Perhaps you
now need to have a prospective trial to further clarify
the importance of the differences in outcome.
I think it would also be important to have the opinion
of a Clinical Oncologist in this area.
Ute Hamann
Deutsches Krebsforschungszentrum Molecular Genetics 
of Breast Cancer, Germany, e-mail: u.hamann@dkfz-
heidelberg.de
Neoadjuvant therapy is a valid option both for
advanced breast cancer and operable breast cancer.
In addition, it improves surgical treatment by increasing
the rate of breast conservation surgery, which minimises
psychological distress for patients fearing mastectomy.
In a recent observational trial conducted among
Polish breast cancer patients the response to different
neoadjuvant chemotherapy regimens was evaluated in
BRCA1 mutation carriers and non-carrier controls.
Interestingly, among women treated with doxetaxel in
combination with doxorubicin the number of responders
was lower in those carrying a BRCA1 mutation than in
those without: six of 15 BRCA1 carriers responded to
treatment compared to 12 of 12 non-carriers. No
difference in the proportion of non-responders in carriers
and non-carriers was found among women who only
received DNA-damaging chemotherapies. Thus, these
data suggest that BRCA1 mutation status is helpful in
selecting patients who may benefit from neoadjuvant
doxetacel and doxorubicin chemotherapy.
The results of the present study are promising
because they provide the first evidence that
neoadjuvant treatment with doxetacel in combination
with doxorubicin may not be an efficient treatment for
BRCA1-associated breast cancer, implying that
alternative neoadjuvant treatments should be offered
to these women. They also support the notion that
expression of normal BRCA1 protein appears to be
required for clinical response to the mitotic spindle
poison docetaxel. However, due to the small size of
this study, the results have to be considered as
preliminary. When being confirmed in other larger
studies, BRCA1 mutation status may be useful as 
a predictive marker for chemosensitivity/resistance to
neoadjuvant treatment with doxetacel and doxorubicin.
A better understanding of the pharmacogenetics in
BRCA1 carriers will allow physicians to individualize
neoadjuvant treatment in these women.
Judy Ho
Hereditary Gastrointestinal Cancer Registry, Hong Kong 
and Department of Surgery, University of Hong Kong Medical
Centre, Queen Mary Hospital, Hong Kong
The article by Byrski et al. is a case-control study
(44 cases matched with 41 controls) conducted in 
18 different hospitals throughout Poland during the
study period. Subjects (both cases and controls) were
unselected, early-onset incident breast cancer patients
undergoing neoadjuvant chemotherapy using a wide
range of chemotherapeutic regimes according to
current local practice. These subjects were stratified
according to their BRCA1 mutation status. Mutational
analysis was carried out on three common founder
mutations in the BRCA1 gene in Poland.
The outcome indicator of chemotherapeutic response
used in this study was the difference in tumour size and
lymph node status (pretreatment vs. post-treatment) which
served as a surrogate indicator of survival rates (on the
assumption that rates of complete response correlate well
with survival rates). In this study, the authors found that
BRCA1 mutation carriers had an inferior response to
docetaxel-containing neoadjuvant chemotherapy
compared with non-carriers.
Although the findings of this current study
corroborate previous results on cell lines, the study
methodology (uncontrolled observational study), the
small sample size and the uncontrolled chemo-
therapeutic regimes used limited the power of this
study. Moreover, as quoted by the authors, various
uncontrolled clinical studies (by Chappius et al.,
Delaloge et al. and Rouzier et al.) on similar topics
yielded results contradictory with the current study.
Hereditary Cancer in Clinical Practice 2007; 5(3)124
Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers
Therefore, further clinical studies, preferably using
controlled data (for example, patients enrolled in 
a randomized controlled trial of breast cancer
chemotherapy or neoadjuvant chemotherapy), to
compare the response to chemotherapeutic agents as
stratified by BRCA1 mutation status, are required to
validate the findings of this study. Otherwise, it is
premature to make any firm recommendation regarding
the routine use of BRCA1 mutation status as a predictor
of the response to and as a guide to the choice of
chemotherapeutic agents in breast cancer.
Evgeny N. Imyanitov
N.N. Petrov Institute of Oncology, St. Petersburg, Russia, 
e-mail: evgeny@imyanitov.spb.ru
Choice of chemotherapy for breast cancer
treatment: will BRCA testing help?
Breast cancer (BC) remains the only cancer type
for which molecular characterization of the tumour is
an absolute prerequisite for consideration of
therapeutic options. However, the use of appropriate
tests is limited to the planning of targeted therapies,
and includes determination of hormone receptor status
for anti-oestrogenic interventions as well as analysis
of HER2 activation for administration of Herceptin. So
far, there is no approved laboratory procedure helping
to select the best regimen for chemotherapy; therefore
the choice of cytotoxic compounds is based mainly on
statistical probability of tumour response. Several
promising observations have been reported in this field,
for example an apparently reproducible association
between amplification and/or overexpression of the
topoisomerase II-alpha (TOP2A) gene and BC
sensitivity to anthracyclines [1]. Nevertheless, the
progress in identification of molecular predictors of BC
response to cytotoxic drugs is surprisingly slow when
compared to some other tumour types, e.g. colon
cancer. Perhaps relatively high response rates of newly
diagnosed breast cancers to any of the standard
treatment schemes (CMF, AC, FAC, AT, etc.) decrease
the motivation to individualize BC chemotherapy.
Byrski et al. [2] have recently reported fascinating
results on the lack of sensitivity of BRCA1-related breast
carcinomas to the best available cytotoxic combination,
namely AT (anthracyclines/taxanes). In their study as many
as 9 out of 15 BRCA1 mutation carriers failed to respond
to neoadjuvant therapy by docetaxel and doxorubicin,
while all 12 non-carriers demonstrated partial response.
Non-taxane combination therapies led to a 100%
response rate in 29 BRCA1-associated cases, although
treatment of non-carriers was also outstandingly
successful (27 responses in 29 patients, 93%). The results
of this study are in perfect agreement with in vitro data
which show resistance of BRCA1-deficient breast cancer
cell lines to taxanes [3].
While distinct aspects of biology and clinical
behaviour of BRCA1-related tumours are the subject of
intensive research, the report of Byrski et al. [2] is only
the second article devoted to comparative analysis of
responses to chemotherapy in carriers vs. non-carriers.
Previously, Chappuis et al. [4] studied the effect of
anthracycline-based therapy and observed exceptionally
high rates of clinical and pathological complete
responses in patients with either BRCA1 or BRCA2
mutation. In addition, Warner et al. [5] published a case
report on the unusually rapid complete clinical and
pathological response of BRCA1-related BC after only
2 cycles of epirubicin-containing scheme.
If replicated in independent studies, the observation
of Byrski et al. [2] may have broad practical
implications. Possibly, all breast cancer patients for
whom neoadjuvant, adjuvant or first-line taxane-
containing therapy is considered as an option have to
be screened against BRCA1 mutation, and the
mutation carriers should be offered an alternative
cytotoxic scheme. While BC cases from communities
with a strong founder effect (Poland, Russia, Ashkenazi
Jews, etc.) require only a limited number of non-
expensive PCR tests, full sequence analysis of the
BRCA1 gene has to be performed in most of the world
[6]. Although the latter option does not look realistic
at present, it may eventually prove to be cost-efficient
by optimizing the spending of highly expensive taxanes
and improving the overall results of BC treatment.
Of course, caution must be taken when interpreting
the data of Byrski et al. [2]. The main difficulty is related
to the low sample size. It is beyond doubt that
evaluation of the predictive role of BRCA genes
requires multicentre research efforts. Given the
relatively high proportion of BRCA1 carriers among
BC cases, frequent use of both taxane-containing and
non-taxane drug combinations, as well as significant
number of yet chemonaive BC patients starting either
neoadjuvant therapy or first-line therapy against
metastatic disease, an appropriate validation study
may be performed within several months.
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At first we would like to recognize the authors for 
a very interesting and well structured study, which
essentially contributes to attempts of more individualized
and effective breast cancer therapy.
Preparing the opinion, we were able to track the
chemotherapy regimens for 23 of our BRCA1 positive
breast cancer cases from Daugavpils regional oncology
hospital. Only in 3 cases was taxane treatment used, in
all cases in an adjuvant setting, when disease progression
(distant metastasis) was detected. In 2 cases disease
progressed in spite of taxane treatment (death and new
distant metastasis respectively). In the last case taxanes
were followed by anthracycline treatment and remission
of the disease was achieved. However, the effectiveness
of taxanes in this case is difficult to evaluate.
5/19 presently published clinical trails on the role
of adjuvant taxane treatment in breast cancer compare
their effect with anthracyclines [1] and there is no clear
evidence that taxanes are more effective than
anthracycline regimens in adjuvant breast cancer
treatment. Therefore in many centres taxanes are not
used as a 1st line treatment and their role still has to
be defined more accurately.
From 1998 to 2000, 26 breast cancer cases in Latvia
underwent neoadjuvant treatment with AT (taxol instead
of docetaxel) regimen and partial or complete
radiological response was observed in 28%. Pathological
response was detected only in 1 case. BRCA1 was not
tested at that time.
Presently there is no clear evidence for the
superiority of neoadjuvant chemotherapy of any
regimen for survival of breast cancer patients and its
main objective is reduction of tumour size to perform
breast conserving treatment. Thus it is clear that the
finding of the authors potentially could affect much
more women deciding on their adjuvant therapy than
neoadjuvant treatment.
The study of Byrski et al. probably also brings the
message that taxanes should not be used as a 2nd line
adjuvant therapy for BRCA1 positive breast cancers 
(in case of disease progression) if further evidence from
other centres is achieved.
Reviewing available preclinical and clinical data on
docetaxel effectiveness in BRCA1 positive breast cancer
cases, many issues are still uncertain and require further
evaluation.
It would be interesting to compare survival data in
different chemotherapy regimen subgroups, in order to
evaluate the ultimate outcome of therapy. It would also
be interesting to extend the study comparing docetaxel
effect in BRCA1 carriers/noncarriers in an adjuvant setting.
The possibility of a multicentre clinical trial comparing
docetaxel vs. other chemotherapy regimens should be
evaluated in populations where BRCA1 testing is
straightforward and economically effective. As taxane
use in breast cancer is still rather centre dependent, 
in our opinion it would be possible to collect enough
cases in both arms.
Summarizing our opinion, we consider it is time to
offer each woman with newly diagnosed breast cancer
the option of BRCA1 testing before the decision about
multimodal therapy, where it is financially (in
populations with a founder effect like Poland, Norway,
Latvia etc.) or medically (criteria of hereditary breast
cancer) justified. This is further supported by other
features specific to the treatment of BRCA1 positive
breast cancers such as the decision about breast
conservative therapy vs. mastectomy, surgical
(salpingoophorectomy) vs. medical therapy (GnRH) in
receptor positive cases of fertile age, and others. At the
same time there is no level I or A evidence-based
confirmation for such clinical practice and this makes
the introduction of routine BRCA1 testing in national
guidelines still rather problematic. Accordingly,
financing of pre-therapy BRCA1 testing from the state
budget would be difficult to justify.
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We also share the opinion that it is time to differentiate
neoadjuvant as well as adjuvant chemotherapy
depending on the presence or absence of a mutation 
in BRCA1 as there are alternative evidence-based
comparably effective chemotherapy regimens available.
Preferably it should be done under clinical trials (or at
least very careful data recording and analysis) in order
to obtain conclusive evidence on the issue as soon 
as possible.
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Responses to neoadjuvant treatment in BRCA1/2
mutation carriers and familial cases: short comment
The recently published paper by Byrski et al. [1]
addressed a major question regarding the response to
chemotherapy of breast tumours occurring in women
carrying a germline BRCA1 mutation. Forty-four carriers
who received neoadjuvant chemotherapy were selected
through screening for three founding BRCA1 Polish
mutations in a series of 3484 women affected with breast
cancer. Only 41 age and hospital matched controls were
selected among the same set of patients. In this
retrospective study, cases and controls experienced
different protocols of chemotherapy. The authors reported
a worse response rate in BRCA1 carriers as compared
to non-carriers (80 vs. 95%, p=0.05) that they attributed
to a lack of sensitivity to docetaxel in carriers.
These results are surprising because of a couple of
facts published in the literature.
Since the BRCA1 protein is involved in the repair of
DNA damage, including double-strand breaks induced
by radiotherapy and chemotherapy, advanced breast
cancers too large to be treated upfront with breast-
conserving surgery could be more chemo- or
radiosensitive in mutation carriers than in non-carriers
[2]. Higher proliferation in BRCA1 mut+tumours, and
their related patterns such as high grade and lack of
oestrogen receptor expression, represents one mechanism
by which BRCA1 mut+tumours are more sensitive to
treatment. Another mechanism might be related to the
loss of bcl-2 expression in BRCA1 mut+tumours, thus
increasing apoptosis in response to treatment [3]. A gene-
expression profile study suggests that BRCA1
mut+tumours display increased expression of genes
associated with inducing apoptosis, and decreased
expression of genes associated with suppressing apoptosis
[4]. In clinical practice, Delaloge et al. [5] showed in 
a small study very high response rates to anthracycline
and cyclophosphamide chemotherapy in BRCA1 carriers.
Chappuis et al. [6] reported that BRCA1/2 carriers
showed a better clinical response rate to neoadjuvant
chemotherapy than non-carriers. The sensitivity to
chemotherapy was confirmed by others studies [7-9].
Indeed, Robson et al. showed that the adjuvant treatment
could modify the prognosis of these patients [10]. The
authors confirmed with this study that the poor prognosis
of BRCA1 mut+tumours described in numerous series
[11-14] is mitigated by adjuvant chemotherapy [10].
In addition, the impact of adjuvant radiotherapy
was shown in 2 studies; with a median 9 and 10-year
follow-up after breast cancer treatment, the rate of
breast recurrence was not higher in BRCA1 and BRCA2
mutation carriers than in patients without family history,
despite more aggressive tumour features and a higher
risk of contralateral breast cancer [15, 16].
As mentioned by Byrski et al. [1] and other studies,
a good sensitivity to chemotherapy and radiotherapy
was expected in BRCA1 mut+tumours according to
the role of BRCA1 in DNA repair [2]. In addition, good
BRCA1 mut+tumour sensitivity to taxanes, mitotic
spindle poisons, might also be expected since a recent
role of BRCA1 has been reported in mitotic spindle
assembly [17].
The study by Byrski et al. [1] is interesting but its
conclusions must be confirmed by larger retrospective
studies or ideally by large prospective multicentre
studies. Indeed, the question is of major interest due
to its clinical importance: early diagnosis by MRI, 
a multidisciplinary approach, and chemo- and
radiotherapy may remain a strong alternative to the
prophylactic mastectomy option.
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The study by Byrski et al. (Breast Cancer Res Treat
2007 May 10 (Epub)) raises interest for both clinical
oncologists and base science investigators as it provides
novel information on the response to neo-adjuvant
chemotherapy of breast cancer women carrying a BRCA1
germ-line mutation. Several studies have reported on
different regimens of chemotherapy in women with breast
cancer, but the response to therapeutic options has not
yet been compared between the sporadic and the
hereditary subgroups.
The report by the Polish Hereditary Breast Cancer
consortium shows that taxane combined with doxorubicin
determines in BRCA1-positive patients a decreased
response as compared to other DNA-damaging
therapies. An increasing number of investigations [for
review see 1] have looked at the major role of BRCA1 as
a modulator of chemotherapy-induced DNA damage.
In particular preclinical studies have pointed out the
interference of damaged BRCA1 in the response to mitotic
spindle poisons. Within these studies it has emerged that
intact BRCA1 protein is required for induction of apoptosis
[2], while downregulation of BRCA1 renders MCF7 cells
insensitive to paclitaxel through inactivation of the spindle
checkpoint [3]. A variety of experimental models
consolidated this evidence [4, 5] and clinical studies
investigating the role of BRCA1 in the response to
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chemotherapy were recommended. One investigation
showed that loss of BRCA1 expression may predict shorter
time to progression in metastatic breast cancers treated
with taxanes; however, no relationship with the clinical
tumour response was observed and no genotyping of
the BRCA1 status was performed [6].
The study by Byrski et al. definitely transfers into the
clinical set the findings achieved in preclinical systems,
offering a provocative turning point which deserves
further studies. As the authors underline, caution should
be exercised in drawing definite conclusions, which
should await a detailed investigation of larger cohorts
of patients. The study compares two small sample sets:
44 Polish women carrying a BRCA1 founder mutation
versus 41 age-and hospital-matched breast cancer
patients (controls).
However, the two patient panels have been sorted
out stepwise from a larger pool of 4316 incident cases
of invasive breast cancer which were identified from
1997 at 18 different Polish hospitals. First 3479 patients
(80.7%) accepted the invitation to participate in the study,
allowing the locally reviewed medical records to be
forwarded to the same centre and evaluated for a set
of fixed parameters. Pathology reviews and mutation
analysis were conducted independently on 3136 and
3472 patients, respectively, and data were then
matched. Yet, according to the study design, the received
neo-adjuvant chemotherapy was the main factor
determining the reduction in the sample and sorting 
820 women out.
Of the 3472 patients 198 (5.7%) were found to carry
a BRCA1 mutation and 44 (29.8%) were treated with
neo-adjuvant chemotherapy, compared with 23.2% 
of the mutation-negative patients. For each BRCA1-positive
case a matched control was selected among those with
available clinical information [41] and the two subgroups
were compared. The statistical significance of group
differences was assessed using the Fisher exact test.
Overall, 35 of the 44 BRCA1 carriers achieved 
a complete or partial response (80%) compared to 
39 of 41 non-carriers (95%; p=005). Focus on users of
taxane-based regimens showed that six of the 15 BRCA1
carriers who were given docetaxel had a response,
compared to 12 of 12 non-carriers (p=0.001).
The authors conclude that the expression of the
wild-type BRCA1 protein is necessary for cancer cells
to respond to spindle poisons such as docetaxel. Their
result that taxanes may not be useful for the treatment
of breast cancer in a significant fraction of BRCA1
carriers is a suggestion which should be validated by
independent studies and should be reconciled with
studies with different indications. Indeed, contrary to
the results of Byrski et al., a small clinical study reported
on the effectiveness of neo-adjuvant chemotherapy in
BRCA1/2 related breast cancer [7], without however
providing enough details on the study design.
Benefits deriving from this study regard the prediction
of scarce sensitivity to taxane of BRCA1-positive patients
in order to avoid unnecessary treatment. Although
BRCA1 carriers represent a small subset of breast cancer
patients, related family members can easily be identified
and appropriate therapy regimens designed also for
those with tumours other than breast cancer. The
advantages stemming from this study could however be
limited if heterogeneity of response exists within BRCA1
mutation carriers due to polymorphisms in genes
involved in taxane transport, oxidative metabolism and
the drug target. Ideally the predictive power of BRCA1
status should be linked to targeted pharmacogenetic
screening, so as to enable the best-tolerated and most
effective treatment strategies. However, inconsistencies
between a few functional polymorphisms and taxane
clearance, outcome and toxicity [8] make currently
unrealistic pre-treatment genotyping of BRCA1 patients
for such pharmacogenetic markers.
Furthermore, recent data on molecular profiling of
docetaxel cytotoxicity in breast cancer cells showing
differences according to drug concentration [9] may have
clinical implications. These, in turn, would provide 
a rational approach to lower the therapeutic
concentrations of docetaxel-based chemotherapy. Insights
from these studies may contribute to optimizing the design
of future prospective clinical studies on BRCA1 carriers
for the development of tailored therapeutic approaches.
The study by Byrski et al. represents an important
achievement in this direction.
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I believe your conclusion of unresponsiveness to
neo-adjuvant therapy in women with BRCA1-positive
breast cancer is most interesting for oncologists and
colleagues attending families with this type of cancer.
In my opinion, it demonstrates that cancer
development and multistep carcinogenesis are dependent
on specific pathways in molecular pathogenesis.
In addition, it is possible that normal BRCA1 is
required for clinical response to mitotic spindle poisons.
Unfortunately, I am an endocrinologist and have
seen many patients with MEN 1, MEN 2, VHL etc., but
not families with familial breast cancer. So my opinion
in this field is limited.
Niklas Loman, Åke Borg
Department of Oncology, Lund University, SE-22185 Lund,
Sweden, e-mail: niklas.loman@med.lu.se
Genetic counselling and BRCA testing in breast and
breast-ovarian cancer families has become state-of-the
art in clinical medicine in large parts of the world during
the last decade. The purpose is risk assessment and
identification of high-risk individuals in order to decrease
the morbidity and mortality associated with the increased
risk of breast, ovarian and possibly other cancers in
mutation carriers. In the treatment of women with breast
cancer, the individual BRCA status may have implications
for the choice of different surgical options such as
mastectomy instead of breast conserving surgery followed
by postoperative radiotherapy, or in performance of
prophylactic contralateral mastectomy and oopho-
rectomy. Furthermore, emerging data suggest that BRCA
status may also have implications for tumour
development, genomics and biology, factors that should
be considered when selecting the appropriate medical
treatment in cases of breast or ovarian cancer.
While displaying different phenotypes, BRCA1 and
BRCA2-associated cancer seem to develop through
pathways that have important features in common. The
typical BRCA1-associated breast cancer is a hormone
receptor negative, non-HER2-amplified, high-grade
ductal carcinoma [1] with an identifiable gene-expression
profile [2] and a cytokeratin profile indicating an origin
in the basal/myoepithelial layer [3]. The phenotype of
BRCA2-associated breast cancer is probably less specific
[4], but also distinguishable from BRCA1-associated and
sporadic breast cancer based on the gene expression
patterns [2]. In addition, a subgroup of sporadic breast
cancer displays similar features as tumours in BRCA1
mutation carriers [5], indicating that lessons learned from
the treatment of BRCA1-associated breast cancer may
also be appropriate for this group of basal-like breast
cancers. Basal-like breast cancers have been shown to
respond well to neo-adjuvant chemotherapy including
paclitaxel, doxorubicin, 5-FU and cyclophosphamide
[6]. However, few clinical studies have been published
to describe the sensitivity of BRCA1-associated cancers
to specific therapeutic measures and possible differences
to other cancers, but experimental data as well as some
retrospective studies suggest that BRCA1-associated
breast and ovarian cancer may have an increased
sensitivity to DNA-interacting chemotherapy compared
with tumours in non-mutation carriers [7-9].
Recently, further data on sensitivity to taxanes in
BRCA1-associated breast cancer were presented in 
a retrospective survey of breast cancer cases [10]. Byrski
and coworkers studied a set of 44 primary BRCA1-positive
breast cancer cases that had all been subject to 
neo-adjuvant chemotherapy. The 44 cases were
compared with 41 age-matched controls that were
negative for three of the founder mutations that are
prevalent in the Polish population (BRCA1 5382insC,
C61G and 4153delA). No difference in the rate of
pathological complete response (pCR) was observed
between the two groups, but a clinical response was more
frequent in controls than in cases. The inferior response
rate among cases seemed to be restricted to the subgroup
of patients receiving docetaxel.
As pointed out by the authors, the retrospective study
design and small size of the study inevitably lead to
difficulties in the interpretation of the data. Nevertheless,
the findings are interesting and should encourage design
of new studies aiming at exploring this important aspect
of breast cancer treatment. Prospective phase-2 studies
are ongoing, both in BRCA1/BRCA2-associated breast
cancer and in “triple negative” breast cancer (correlating
with the basal-like phenotype), comparing taxane with
carboplatin therapy in the metastatic setting. More clinical
evidence is awaited through gene expression profiling of
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tumours in large prospective adjuvant and neo-adjuvant
phase-3 trials where response has been prospectively
assessed. In addition, retrospective BRCA testing should
be attempted in studies of similar design. The results of
these ethically and practically challenging tasks should
be evaluated before considering applying BRCA status
as a predictive factor in the (neo-) adjuvant treatment of
early breast cancer.
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Preoperative BRCA testing in breast cancer
Testing for BRCA mutations is about to become part
of the diagnostic procedures to select treatment for
breast cancer patients.
In a recent report, Byrski et al. [1] concluded that
neo-adjuvant chemotherapy with docetaxel had no
effect in BRCA1 mutation carrying women with breast
cancer. This is important, because the prognosis of
BRCA1 induced breast cancer is poor with today’s
treatment [2], and it is of obvious interest to determine
which treatment regimens work and which do not.
Docetaxel is probably not effective to treat BRCA1
breast cancer. Having that knowledge, patients could
be subjected to other treatment regimens which may
be beneficial, the cost of trying docetaxel could be
avoided, and the patients could be relieved from the
side effects of docetaxel. Instead of doing a neo-
adjuvant trial in each patient, the patients may be
tested for BRCA1 mutations. This is an argument to
include BRCA mutation testing in the pre-treatment
diagnostic procedures to select adjuvant chemotherapy.
An argument for pre-operative BRCA testing of breast
cancer patients is to determine the surgical procedure.
Patients with small tumours are today offered to choose
breast conserving treatment, which includes postoperative
radiation therapy. BRCA mutation carriers have, however,
high risk for a contralateral tumour, and may be
candidates for contralateral prophylactic mastectomy with
reconstruction. If so, radiation treatment of the ipsilateral
side should be avoided – surgical treatment should be
ablatio with the option of bilateral reconstruction. That
is, BRCA testing should be completed before selecting
surgical treatment. Such rapid testing will – for practical
purposes – only be available for locally frequent founder
mutations. It is no coincidence that Byrski et al.’s report
emerges from a population with established rapid tests
for founder mutations. In Norway, all professional
groups treating breast and ovarian cancer have
suggested to the authorities to institute rapid testing for
founder BRCA mutations for all incident breast or
ovarian cancers [3, 4]. In that population, the test panel
will identify about 70% of all mutation carriers. It is
doable to streamline the test procedure to have the test
results within two weeks.
Also, there is an argument to identify BRCA1
mutation carriers among breast cancer patients, so as
to improve the prognosis by oophorectomy [2].
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Tailoring therapy in breast cancer in relation 
to aetiological factors
Evidence is accumulating that the biology of breast
cancer at least partly is related to aetiological factors
and the state/origin of the epithelial cell at time of
initiation. This has been postulated before in relation
to hormonal and genetic risk factors in breast cancer
[1-3] and supported by results from gene expression
analysis [4-7] and breast cancer stem cell research 
[8-10]. The alternative hypothesis would suggest that
cancer development is a random process affecting 
a common breast stem cell and that the biology would
depend on crucial genes mutated in a random fashion.
The age of a tumour would in this setting be more
important as tumour progression would increase by the
inherent genetic instability and make therapy less
successful late in the disease course. The first hypothesis
would make tumours more stable during disease
course (more dependent on the origin of the tumour
cell than the progression) and it would therefore both
in the neoadjuvant and in the advanced stage be
possible to give a tailored treatment affecting crucial
growth factor pathways.
The results by Byrski et al. 2007 [11] looking at
neoadjuvant chemotherapy in BRCA1 carriers in Poland
is still another study suggesting the value of tailored
therapy in hereditary breast cancer and favouring the
first hypothesis, as they found that taxane chemotherapy
was less effective as neoadjuvant therapy than other
therapy combinations.
In patients with BRCA1 and BRCA2 mutations studies
are already underway to assess if tailored therapy in the
form of platinol or mitomycin containing chemotherapy
or use of PARP inhibitors improve metastatic therapy 
[12-14]. Case stories and animal models support this
approach.
Two questions are pertinent in relation to the recent
results: should all breast and ovarian cancer patients
be offered BRCA1/2 testing before therapy is initiated,
and in the clinic, should neoadjuvant therapy already
be differentiated depending on BRCA1 mutations?
Except for some populations having very strong
BRCA1/2 founder mutations, so far data indicate that
most BRCA1/2 carriers with breast cancer are identified
through family history. In unselected breast cancer
populations regardless of age they would account for
not more than 1-2% of cases. For ovarian cancer this
would be higher, 10-15%, but again most of the
patients would be identified through a family history.
Therefore it is questionable to test all patients with
breast cancer except for situations were family histories
would not be present or reliable or if the patient
originates from a geographic/ethnic area with very
strong founder mutations. However, patients with 
a strong family history should be offered testing now
for two reasons: first to assess the risk for the individual
and later the family; secondly a positive mutation test
may indeed affect primary therapy and patient
recruitment into randomised trials.
Is there a case for offering BRCA1 patients in the
clinic differentiated neoadjuvant therapy? So far studies
are retrospective and nonrandomised. The undertaking
of a randomised prospective pan-European or
worldwide study would be optimal to support clinical
care. Unfortunately it might be difficult to achieve
enough power within a reasonable time to answer the
research question. Outside the scope of such a trial,
data indicate for clinicians that regimens containing
platinol and mitomycin should be favoured in therapy
of BRCA1 associated breast and ovarian cancer, while
taxanes are not a first choice.
Is there an even wider scope of this reasoning? How
about tumours similar in phenotype to BRCA1 tumours
(e.g. triple negative breast cancer)? Would these tumours
benefit from the same regimens that turn out to be
effective in BRCA1 [15, 16]? Again there is a need for
randomised studies to assess this. The timeframe for
studying these basal like tumours may be easier as this
would constitute a larger group of breast cancer than
only BRCA1 mutation carriers.
However, recent data suggest that the tumour
phenotype defined by expression analysis does not
consistently predict tumour response in locally advanced
tumours [15], again corroborating the fact that there is
a need to bring tumour biological data together with
aetiological risk factor data such as Byrski et al. has done
to find out if therapy prediction could be improved.
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I do agree with Jan and Rodney that because we
have good in vitro and matched observational studies
which suggest inborn resistance to taxane in the
mutational group, I am also with you that we could
suggest the idea that in the mutation carrier group in
breast cancer taxane should be avoided and appropriate
choice of chemotherapy would be very important.
Second, for the screening of BRCA1 in general
patients, it might be considerable, but because the
incidence will be too low and some cost and benefit
issues should be considered as well, my opinion is that
we have to select, for example, in addition to those
familial candidates, younger patients with little response
to taxane, or triple negative cases, etc.
Sinisa Raduloviæ, Mira Brankoviæ-Magiæ
Institute for Oncology and Radiology of Serbia, Belgrade,
Serbia and Montenegro
Is the BRCA1 gene a useful predictive marker for
(neo-adjuvant) chemotherapy choice in breast
cancer?
In the recent issue of Breast Cancer Research and
Treatment Journal members of the Polish Hereditary
Breast Cancer Consortium published an interesting
article concerning the response to neoadjuvant
chemotherapy in BRCA1 germ-line mutation carriers
[1]. They identified 44 Polish women with a BRCA1
mutation who had been treated with neo-adjuvant
chemotherapy. Response rate (by their criteria, i.e.
complete disappearance or any decrease in size of the
tumour) was found to be lower in BRCA1 mutation
carriers (80%) in comparison to the response rate of
matched mutation-negative breast cancer controls
(95%). Interestingly, only 6 out of 15 BRCA1 carriers
obtained responses to a chemotherapy regimen
containing docetaxel compared to a 100% response
rate in 20 BRCA1 carriers receiving chemotherapy
without docetaxel. Nine women with BRCA1 mutations
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did not achieve tumour response to docetaxel-
containing chemotherapy.
The majority of non-carriers responded to neo-
adjuvant chemotherapy, 12 out of 12 to docetaxel-
containing and 27 out of 29 to non-docetaxel
regimens. The authors concluded that BRCA1 mutation
carriers frequently lack sensitivity to docetaxel in the
neo-adjuvant setting and that functional BRCA1 is
required for the tumour shrinkage to spindle poisons.
Neo-adjuvant chemotherapy is increasingly being
used for treatment of early-stage and locally advanced
breast cancer. The theory behind this is to decrease the
size of the tumour, allowing breast conserving surgery,
to look in-vivo at the drug sensitivity, and to use active
systemic treatment of micrometastasis, achieving longer
disease-free and overall survival. Clearly, neo-adjuvant
chemotherapy increases the frequency of breast
conserving surgery but does not prolong overall survival
compared with adjuvant chemotherapy. However,
patients achieving pathologic complete response have
significantly prolonged disease-free and overall survival
after neo-adjuvant chemotherapy [2]. Today, pathologic
complete response is considered to be a surrogate
marker for favourable prognosis of neo-adjuvant
chemotherapy, but it is achieved only in 3-30% of
patients [3]. Pathologic complete response has recently
been defined as no invasive or noninvasive tumours in
the breast and axillary tissue removed at the time of
surgery [4]. In the article by Byrski and colleagues
pathologic complete responses were achieved in 4 of
44 (9.1%) BRCA1 mutation carriers and in 2 of 41
(4.9%) non-carriers. They stated that residual tumours
were not identified in the breast tissue but the status of
the axillary nodes was not mentioned. Interestingly, no
single patient, regardless of BRCA1 mutation status,
achieved (pathologic) complete response to docetaxel
(total number of 27 patients), i.e. all 6 complete
responders received FAC (5 patients) or AC regimen
(1 patient). This is in contrast to NSABP B-27 results,
where pathologic response was 19% in the
combinational chemotherapy plus docetaxel compared
with 9% in the combinational (AC) therapy arm alone
[5]. However, increased pathologic complete response
with more effective drugs, such as docetaxel, has not
led to consistent improvement in survival.
So, what are the factors that might affect sensitivity
to neo-adjuvant chemotherapy? There are some
identified predictive factors associated with pathologic
complete response such as hormone receptor status
(response significantly higher in hormone receptor-
negative tumours), pathologic characteristics (invasive
lobular carcinoma are less likely to achieve response
compared to invasive ductal carcinoma, and poor
differentiation, high nuclear grade and high
proliferation index are predictors for the response to
chemotherapy) and, finally, status (amplification) of
HER2 could predict response to chemotherapy plus
trastuzumab. In the article by Byrski and colleagues,
lobular carcinoma was diagnosed in 2.3% and 14.6%
of patients with and without BRCA1 mutations,
respectively. Oestrogen receptor negativity was twice
as frequent in the BRCA1 carrier group (90.9%)
compared with the non-carrier group (43.9%). The
situation is similar for progesterone receptor negativity.
Higher incidence of HER2 positive tumours in the
control group (26.8%) than in BRCA1 carriers (18.2%)
was observed. All of these parameters should be taken
into consideration when analysing the results of the
Polish Hereditary Breast Cancer Consortium data.
Finally, many studies have been done by using DNA
microarrays and expression of large numbers of genes
in order to find groups of genes that might be
associated with drug sensitivity in neo-adjuvant
chemotherapy. None of them, although most of these
studies are on an insufficient number of patients, was
able to identify any gene(s) as a predictive factor for
drug sensitivity. Is BRCA1 one of them, at least in
relation to docetaxel chemotherapy?
The role of BRCA1 in the cellular response to
chemotherapy has been reviewed [6]. The major role
for BRCA1 is to respond to DNA damage by
participating in cellular pathways for DNA repair, mRNA
transcription, cell cycle regulation, and protein
ubiquitination. Although the BRCA1 gene is a DNA
damage response gene, it also appears to play a role
in the regulation of mitotic process and, in such way,
BRCA1 is involved in the response to docetaxel and
paclitaxel. Binding of BRCA1 to γ-tubulin is involved in
the correct segregation of chromosomes during mitosis
[7]. Mutation of exon 11 of BRCA1 leads to
chromosomal instability, i.e. intact BRCA1 participates
in the defection of abnormal mitosis and in the
induction of apoptosis to prevent the replication of
aneuploid cells [8]. An additional mechanism by which
BRCA1 participates in sensitivity to spindle poisons may
involve the c-jun N-terminal kinase (JNK) pathway,
which is specifically activated after treatment with
paclitaxel. The loss of BRCA1 expression results in
decreased JNK activation after paclitaxel treatment [9].
Preclinical studies indicated that BRCA1 is required
for paclitaxel sensitivity in breast cancer cell lines. Two
groups [10, 11] reported significant increase to spindle
poison (paclitaxel and vinorelbin) when functional
BRCA1 was reconstituted into the HCC1937 cells.
However, decreased paclitaxel sensitivity was reported
when BRCA1 was expressed in the BRCA1-mutant 
SNU-251 human ovarian cell line [12]. Overall, BRCA1
is required for the induction of apoptosis in response to
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spindle poison (just to mention here that paclitaxel and
docetaxel have not exactly the same mechanism of
action), particularly in breast cancer cells.
The role of the BRCA1 gene in response to spindle
poisons in clinical studies has been less characterised.
Some findings are in a disagreement with preclinical
studies. Egawa et al. [13] demonstrated that lower
expression of BRCA1 mRNA is associated with
increased sensitivity to docetaxel. What is clear from
the clinical data, BRCA1 inactivation through mutation
confers sensitivity to DNA-damaging drugs. In the
article by Byrski et al. mutation carriers not responding
to docetaxel also received doxorubicin, which is 
a DNA-damaging agent. Is it possible that docetaxel
“protects” tumour cells from cytotoxic action of
doxorubicin? Obviously, the use of a single agent
would allow much better understanding of BRCA1
mutation and response to a particular drug.
The obtained data indicate that patients who need
neoadjuvant treatment with docetaxel regimens have to
be tested for the presence of BRCA1 mutation. BRCA1
mutation presence is a rare event in sporadic breast
cancer and the “gold standard” for BRCA1 testing still
implies sequencing of the entire coding region of the
gene. It seems that BRCA1 testing for neoadjuvant
chemotherapy may be necessary, but in practice cannot
be performed in all countries, especially in countries
where “founder” mutations have not been detected or
their proportion is small.
As the authors pointed out, their study is observational
and not conclusive, but the work is interesting and
intriguing enough to facilitate further clinical prospective
studies investigating the role of BRCA1 mutations in the
response to chemotherapy.
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I have gone through the paper and feel it is valid
to offer BRCA1 testing if the patient is planned for
taxanes. In our own group of patients, which at present
is small, we have not yet had use of taxanes as neo-
adjuvant therapy. In our Institution, we plan for
concurrent chemo and radiotherapy, either with CMF
or FAC, for locally advanced breast cancers.
Evangelia Razis1, Drakoulis Yannoukakos2
1Diagnostic and Therapeutic Centre of Athens HYGEIA, Athens,
Greece
2Molecular Diagnostics Laboratory, IRRP, National Centre 
for Scientific Research “Demokritos”, Athens, Greece
Docetaxel (in)sensitivity in BRCA1-positive breast
cancers?
In a recent article in the New England Journal of
Medicine [1], it was shown that, despite what was
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previously believed, BRCA1 gene mutation carriers do
not carry a worse prognosis than other breast cancer
patients. However, there is a mounting body of evidence
indicating that BRCA1 mutations may affect sensitivity to
specific chemotherapy agents.
The BRCA1 gene is mutated in approximately 5% of
breast cancers but is also under-expressed in several
sporadic cancers. The BRCA1 gene, located on
chromosome 17, encodes a 220-kDa protein that is
responsible for DNA damage repair, cell cycle regulation,
mRNA transcription and protein ubiquitination [2].
BRCA1 is phosphorylated by the ataxia-telangiectasia
mutated (ATM) protein in response to DNA damage.
Many chemotherapeutic agents act by causing direct
DNA damage via interstrand cross-links (alkylators,
anthracyclines), DNA adducts (platinum agents) and
double strand breaks (bleomycin). BRCA1 activation is
part of the DNA repair process. In sporadic cancers with
low levels of BRCA1 expression, there is little proof of
differential sensitivity to chemotherapy agents [3].
However, in BRCA1 loss, both preclinical and clinical
studies have shown that response to DNA damaging
agents is increased [4, 5].
Another class of antineoplastic agents is the
microtubule poisons. Those act by either blocking or
promoting the depolymerization of the microtubules in
the mitotic spindle, leading to apoptosis. Spindle-poison-
induced apoptosis is regulated by the c-jun N-terminal
kinase (JNK) pathway [6]. BRCA1 is also involved in the
regulation of mitosis through the JNK pathway and its
increased expression has been shown to induce
apoptosis caused by microtubule poisons. Thus BRCA1
mutation carriers are bound to be less sensitive to
taxanes, the latter being microtubule poisons.
In the study by Byrski el al. [7] the response 
of 44 BRCA1 mutation carriers with breast cancer to
neoadjuvant therapy was compared to that of 41 age-
and hospital-matched controls. The response of non-
carriers was higher than that of carriers, and within the
hereditary group, docetaxel treated patients did
significantly worse than those that did not receive
docetaxel. Within the non-carrier group there was no
difference in response according to the use of
docetaxel. Non-taxane based regimens included FAC,
AC, CMF and CMFP, whereas docetaxel was given
always in combination with doxorubicin. It is thus
impossible to “tease out” the effect of BRCA1 on
doxorubicin sensitivity from that on docetaxel sensitivity.
Furthermore, the numbers of patients in each subgroup
are too small to yield strong results.
Other authors have attempted to look at the effect
of BRCA1 on taxane efficacy. On cell lines this has
been tested repeatedly, always yielding the same result:
namely, that the loss of BRCA1 function leads to taxane
resistance [8, 9]. In the clinic, a Japanese study showed
that time to disease progression after treatment with
taxanes was shorter for BRCA1 mutation carriers than
for non-carriers [10]. Egawa el al. on the other hand
found that increased BRCA1 mRNA expression led to
increased response to docetaxel [3].
More evidence is provided by studies regarding the
chemosensitivity of triple negative or basal-like cancers.
BRCA1 related cancers are frequently triple negative.
Triple negative cancers responded particularly well to
neoadjuvant paclitaxel-FAC in a study by Rouzier et al.
[11]. However, as noted in the study by Byrski et al.,
not all triple negative cancers are BRCA1 mutant.
Additionally, at this point BRCA1 patients’ sensitivity to
taxanes appears to be more related to the absence of
the BRCA1 promoting effect on the microtubule
checkpoint than to the absence of hormone receptors.
Though the results of the study by Byrski et al. are
consistent with the theoretical models, preclinical and
clinical studies, they have to be approached with
caution because the study is not prospective and the
number of patients is small. Finally, the confounding
variable of several different regimens and different
agents (with variable efficacy in BRCA1 patients) may
cloud the issue further. However, there is at this point
so much corroborative evidence regarding the effect
of BRCA1 on chemotherapy efficacy that the need for
prospective studies in this field is imperative.
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Is BRCA1 a possible predictor of response to 
neo-adjuvant chemotherapy?
BRCA1 is an important gene of breast cancer
susceptibility [1]. Germinal mutations in this gene are
responsible for 5% of all breast cancer cases and the
tumours that arise in this setting share some special
histological characteristics such as high grade, pushing
margins, ER and HER2 negativity, frequently P53
mutations and basal phenotype. The normal BRCA1
functions are related to DNA repair and cell cycle control
and recently it was demonstrated that the BRCA1 status
can predict response to chemotherapy [2]. Recently, Byrski
et al. [3] showed that cases of breast cancer in BRCA1
mutation carriers had a lower response to docetaxel when
compared with non-carriers (80 vs. 95%) and these
authors conclude that breast cancers among BRCA1
carriers frequently do not exhibit sensitivity to taxanes
(docetaxel) in the neoadjuvant setting. BRCA1 may
increase cell sensitivity to spindle poisons by signalling 
a pro-apoptotic pathway in response to spindle damage.
In the absence of functional BRCA1, the mitotic spindle
checkpoint is not activated and apoptosis is not induced.
However, as recognized by the authors this study is an
observational study, with a small number of patients 
and without a standard protocol. Patients also received
other different drugs, such as doxorubicin, which is 
a DNA-damaging drug, and in this case a lack of
functional BRCA1 and P53 (frequently mutated in these
patients) genes leads to better response to treatment. So,
to clarify the role of taxanes in BRCA1 mutated patients
still requires a large, randomized and prospective study.
However, two important questions should be
highlighted concerning BRCA1 and chemotherapy.
First, there is no doubt that there is much evidence
showing that BRCA1 can be a good predictor of
response to chemotherapy, not only resistance but also
sensitivity. Rosell et al. [4] showed that low levels of
BRCA1 mRNA significantly increased survival in
gemcitabine/cisplatin-treated patients. Recently, a high
clinical response to anthracyclines in BRCA1 carriers
with breast cancer was demonstrated [5]. This drug
inhibits topoisomerase 2a, leading to interruption of
DNA replication and damage to the double helix that
cannot be repaired in BRCA1 deficient cells. There is
also evidence that medullary breast carcinomas are
chemosensitive for some drugs and we know that MBC
are frequent in BRCA1 carriers [6].
Is it time to offer each woman with a newly diagnosed
breast cancer the option of BRCA1 testing? I am not sure.
First, there are established clinical and pathological
criteria to raise the suspicion of hereditary breast cancer
and of course these cases should be investigated.
Second, there is evidence that BRCA1 can be deficient
in some non-hereditary cancers by mechanisms other
than mutations. In basal-like breast carcinomas (high
grade breast carcinomas, ER and HER2 negative and
positive for a basal marker) [7] BRCA1 inactivation by
methylation or by over-expression of inhibitors like ID4
[8] was demonstrated. Probably theses cases also have
benefits using specific chemotherapy and the analysis of
mutations will be negative. However, it is important to
stress that not only for BRCA1 but also for other genes,
like P53, chemotherapy in breast cancer will be guided
according to specific gene alterations. In fact, recently
Rottenberg et al. [9] studying the responses of
spontaneous BRCA1 and P53-deficient mammary
tumours arising in conditional mouse mutations to
doxorubicin, docetaxel and cisplatin showed that the
response of individual cases varies, but eventually all
become resistant to the maximum tolerable dose of
doxorubicin or docetaxel but still respond well to cisplatin
even after multiple treatments in recurrences.
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Thank you very much for calling my attention to
your interesting article that provides the basis for the
initiation of RCTs to compare taxane-based versus
platin-based neo-adjuvant regimens.
Although we do not have data on neo-adjuvant
therapy we have seen a very dramatic response
(complete remission!) of an extensive local relapse
(chest wall recurrence with multiple axillary lymph nodes
combined with a severe oedema of the whole arm) in
a BRCA1 mutation carrier when administering
carboplatin second line after taxane mono first line was
terminated because of progressive disease.
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1Consultant in Medical Oncology, Southampton University
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We read with interest the paper of Byrski et al.
outlining their observations of differential responses to
neoadjuvant taxane containing chemotherapy in breast
cancer cases arising in BRCA1 gene carriers and non-
carriers. The question of how BRCA1 and BRCA2
mutation status might influence the response to treatment
is of great interest clinically and the findings presented
are in line with what might be expected from the
published data from in vitro experiments in BRCA1 and
BRCA2 null cell lines. However, although interesting, the
data presented are not sufficiently robust to alter current
clinical management in BRCA1 gene carriers.
Breast cancer cases were all in younger women and
gene carrier ages were matched with non-carrier ages.
Only the Polish founder mutations have been identified;
presumably cases did not have full BRCA1 and BRCA2
mutation testing so that there are plausibly a number
of gene carriers represented within the “non-carriers”.
This is particularly true as 41.5% of the “non-carriers”
had a family history (presumably of breast cancer) and
36.5% of these same “non-carriers” had missing family
history data.
The response to neoadjuvant chemotherapy was
obtained from chart review (it is not clear whether 
the genetic status of the patients was known to the
clinician extracting the information from the case notes)
and pathology assessment. Comparison between clinical
assessment of tumour size at presentation and patho-
logical assessment of size at completion of chemotherapy
is problematic. Using two different methods of assessment
has inherent inaccuracies.
Imaging assessment generally includes invasive and
non-invasive components of the tumour. It is unclear
what is included in the pathological assessment of
tumour size but if it is invasive tumour only, tumours
that have a significant component of non-invasive
tumour will appear to shrink less than those which are
predominantly invasive tumour (perhaps more likely in
BRCA1 associated tumours). Clinical assessment of
axillary lymph node involvement is unreliable. It is not
clear that all patients that were classified as node
positive preoperatively had cytological confirmation.
The vast majority of breast cancers in both carriers
and non-carriers seem to have had a partial response
to any neoadjuvant chemotherapy and all patients who
received docetaxel also received doxorubicin, which
would be anticipated to be effective in BRCA1 mutation
carriers. Patients were only matched for centre, age at
diagnosis and year of birth. There was no attempt to
match for other important determinants of prognosis
such as tumour size, grade (no information has been
given about tumour grade), ER status, Her2 status, or
nodal status. There are important imbalances in some
of these prognostic factors between the groups.
Finally, since no significant difference in mortality was
observed between the groups, it would be premature to
use these data to recommend a change in treatment.
However, a well designed prospective randomised trial
comparing two neoadjuvant treatment regimens with
and without docetaxel would be an option to explore
this observation further. A population with well recognised
founder mutations in BRCA1 would be ideal as early and
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rapid genetic testing can be offered in such a population
at the time of diagnosis, and cases matched for all major
prognostic tumour factors but highly unlikely to be gene
carriers (founder mutations excluded and no significant
family history) would allow a better assessment of the
role of BRCA1 mutation status in independently
influencing the outcome of treatment.
Jacob Smeltzer, Peter T. Silberstein1,
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1Creighton University Division of Hematology/Oncology,
Omaha, USA
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Personalized chemotherapy for BRCA1 mutation-
positive patients
Why should we treat all hereditary breast cancer
(HBC) syndrome affected patients as if they were
clinically, genetically, and pathogenically the same
disease? Byrski et al. [1], in recognizing the etiologic,
pathologic, and clinical variability of selected breast
cancer cases, provide preliminary evidence that BRCA1
patients are less responsive to taxane-based therapy
when compared with their BRCA2 and sporadic breast
cancer counterparts. This is a reasonable supposition
in that there is voluminous evidence supporting the
hypothesis that breast cancer shows marked differences
in sporadic and in the several hereditary varieties of
this disease. Hence, it should not be surprising that
hereditary cases may differ in response to therapy. For
example, BRCA1 HBC frequently harbors a distinctive
pathology phenotype, consisting of an increased
number of aneuploid cancers, more medullary
carcinomas, and high proliferation rates as measured
by DNA flow cytometry and mitotic grade, with less
ductal carcinoma in situ (DCIS) than in non-familial
cases [2-4]. The high S-phase fraction has been
attributed to a BRCA1-linked subset, which is in accord
with the suggestion that the BRCA1 mutation is
predisposed to enhanced cellular proliferation [5].
This model for the BRCA1 phenotype considers the
tumors to be in an advanced state of genetic evolution
[2]. In contrast, the “other” HBCs with BRCA2 mutations
with 15q linkage appear to lack the high-grade,
aneuploidy, and high proliferation of BRCA1 HBCs; in
addition, they are not deficient in in situ carcinoma 
[2, 3]. This “other” group also has more invasive, lobular,
tubular-lobular, and cribriform histologies, and when
pathologically aggregated they fit mutation-confirmed
BRCA2 HBC cases and appear more like breast cancer
occurrence in the general population [4]. Yet to be
explored are the histopathology and clinical features in
a litany of other HBC-prone syndromes such as breast
cancer patients with Li-Fraumeni syndrome (p53 germline
mutation), Peutz-Jeghers syndrome (STK11 mutation),
and the CHEK2 mutation, which is believed to be the
most common breast-cancer predisposing mutation to
have been discovered since the BRCA mutations’
identification in the mid-1990s [6, 7].
BRCA1 is a key tumor suppressor gene, and
mutations in it markedly increase the risk of breast and
ovarian cancer. Functionally, this gene is an integral
component in recognizing and repairing double-
stranded DNA damage, upregulates p53, and
mediates nucleotide excision repair [8]. It also has a
significant role in cellular microtubule damage.
Understanding the molecular function of BRCA1 will
help to predict response to different chemotherapies
that are modulated by BRCA1 interaction with the
drug’s mechanism of action.
As BRCA1 is key to repairing double-stranded breaks
in an error-free fashion, hereditary deficiency in BRCA1
leaves cells particularly vulnerable to DNA damage.
Alkylating agents, platinum agents, anthracyclines 
and topoisomerase inhibitors, which are drugs that
facilitate double-stranded breaks, are more potent 
in BRCA1 deficient cells than wild-type cells by taking
advantage of the cells’ increased vulnerability. [8]. 
Cancer cells that are resistant to cisplatin have been
shown to be overexpressing BRCA1 and have increased
BRCA1-dependent DNA repair [9]. Furthermore, inhibition
of BRCA1 by antisense RNA leads to a corresponding
increase in cisplatin sensitivity [10].
Understanding BRCA1 function can help us
understand which chemotherapies will be effective in
killing cancer cells as well as those to which the cancer
cells will most likely have resistance. BRCA1 has a role
in sensing microtubule damage and, through the Jun 
N-terminal kinase (JNK) pathway, facilitating cell cycle
arrest. Unlike its role with DNA-damaging chemothe-
rapies, BRCA1 deficiency leads to resistance to
microtubule chemotherapies [8]. Complementing this
knowledge, cell lines resistant to the taxane drug paclitaxel,
which acts on the microtubules, have then been
reconstituted to wild-type BRCA1 and had a 1000-fold
increase in sensitivity [11].
The limited retrospective neoadjuvant chemotherapy
studies show that BRCA1 mutation carriers have greater
clinical response and are more chemosensitive than wild
types. In the Chappius study, 10/11 BRCA1/2 mutation
carriers vs. 2/11 noncarriers had complete clinical
response to neoadjuvant therapy for breast cancer [12].
Delaloge found a 100% clinical response in BRCA1
patients, an 80% response in BRCA2 patients, and 
63% in noncarriers in the neoadjuvant setting, as well
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as a significantly higher rate of pathological complete
response in BRCA1 patients [13]. Both studies used 
DNA double-strand-damaging anthracycline-based
chemotherapies and found greater clinical sensitivity 
in BRCA1 patients.
Ovarian cancer patients with BRCA1 mutations
show increased sensitivity to the platinum DNA
damaging agents similar to that exhibited by breast
cancer BRCA1 cells [8]. Husain showed that antisense
inhibition of BRCA1 restored cisplatin chemosensitivity
in ovarian cancer cell lines that were previously resistant
to cisplatin [9]. Cass compared the survival rate of
Jewish ovarian cancer patients who had BRCA1
mutations, BRCA2 mutations, and no mutations. The
median survival of the BRCA patients was higher than
those without mutations. Eighty-six percent of the BRCA
heterozygotes responded to chemotherapy while only
41% of the sporadic patients responded (p=0.01). All
patients were treated with carboplatin, and the majority
received that drug in combination with paclitaxel [14].
Rennert recently showed that the prognosis may be
similar for BRCA1 patients and sporadic breast cancer
patients [15]. However, in previous studies BRCA1 status
was a negative predictor of prognosis. Specifically, in the
subset of patients not receiving adjuvant chemotherapy,
BRCA1 patients had worse overall survival than non-
carriers [16]. In Rennert’s study, BRCA1 patients receiving
chemotherapy had improved overall survival compared
to non-BRCA1 breast cancer patients [15]. The use of
chemotherapy appears to be of particular importance to
the survival of BRCA1 patients.
Can we learn about a differential response to
chemotherapy by studying other hereditary cancer-
prone disorders, such as the Lynch syndrome? Boland
[17] has recently reviewed the relationship between 
5-fluorouracil (5-FU) and its response to microsatellite
instability positivity (MSI+). Even the long-known fact
that a DNA mismatch repair (MMR) system is involved
“...in signaling a cell death response after sufficiently
toxic DNA damage, and that DNA MMR-deficient cells
are relatively tolerant to DNA damage [18, 19]. It was
subsequently found that this is also true for CRC cells,
and that restoration of the MMR system would restore
sensitivity to several compounds that damage DNA
[20, 21], including chemotherapeutic agents such as
fluorouracil (FU) [22]. Thus, the prediction was made
that patients with MSI CRCs would be relatively resistant
to the beneficial effects of FU-based regimens.” [17].
Lynch et al. [23], in evaluating the role of chemotherapy,
particularly FU, noted that it is important to make the
distinction between those CRC affecteds with MSI+ vs. those
that are microsatellite stable (MSS). Ribic, in a large,
prospective, randomized study of chemotherapy,
demonstrated that 5-FU was a benefit to patients with CRCs
that were MSS, but a modest 2-fold hazard ratio for death
was found among those patients who received 5-FU if their
tumor was MSI+ [24]. In reviewing this subject, Lynch et al.
suggest that“ The issue of survival will confound studies
that are not prospectively randomized and stratified for MSI
status. Nonetheless, a failure to demonstrate survival
benefits after adjuvant chemotherapy in patients with MSI+
tumors or with Lynch syndrome has been demonstrated by
most subsequent investigators [25-28]” [23].
Fallik et al. [29] showed that MSI+ tumors with
metastatic colorectal cancer had a better response to
the topoisomerase I inhibitor, irinotecan. Based on this
study, Lynch et al. have stated that “...it is reasonable
to consider the planning of future clinical trials in which
non-5FU-based chemotherapy will be used in the
adjuvant setting for patients with Lynch syndrome, as
well as for other patients with advanced MSI+ cancers.
Also, as there are important biological differences
between Lynch syndrome tumors and sporadic MSI+
tumors (which are caused by epigenetic silencing of
MLH1 and other tumor suppressor genes), these groups
may need to be considered separately” [23].
The recent article by Byrski et al. [1] clinically correlates
well with the understanding of BRCA1 functionality in
breast cancer patients undergoing neoadjuvant
chemotherapy. While the numbers are small, BRCA1
patients demonstrated particular resistance to the
microtubule chemotherapy, docetaxel. Only 6/15 BRCA1
patients were responsive to docetaxel vs. 12/12
noncarriers, highlighting the specific resistance of BRCA1
patients to docetaxel. Regardless of ER/PR or Her-2 Neu
status, BRCA1 status appears to be an independent
negative predictor of response to taxane chemotherapy
[1]. Given the success of taxane chemotherapies in breast
cancer, this knowledge of resistance to taxane in breast
cancer patients carrying BRCA1 mutations is particularly
important. BRCA1 patients responded better to
Adriamycin than non-BRCA1 patients and the BRCA1
patients had a greater complete response (4/19 vs. 2/18)
and fewer non-responses (0/19 vs. 2/18) than the 
non-BRCA1 patients [1]. Though not analyzed in the
paper for significance, this appears to fit with the
previously suggested role of BRCA1 as a marker for
sensitivity to DNA damaging chemotherapies.
Boyd analyzed the Sloan-Kettering’s and
Gynecological Oncology Group’s ovarian cancer
patients and found that patients with BRCA mutations
lived longer than non-hereditary patients. The BRCA
patients did not have a higher response rate to
chemotherapy but had a longer disease-free survival
than the non-hereditary patients [30]. They evaluated
patients in the GOG Trial #111 who were given
cisplatinum in addition to either cyclophosphamide or
paclitaxel. They did not report on the differential response
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to paclitaxel/cyclophosphamide in patients with BRCA1.
The preclinical data and Byrski’s report would suggest
that the BRCA1 patients might respond poorly to
paclitaxel. This might be an area of future investigation.
Given that BRCA1 acts by repairing double-stranded
DNA damage, preclinical as well as in vivo reports such
as the recent report by Byrski suggest that BRCA1 patients
should respond well to anthracyclines, platinums,
alkylating agents, and less well to taxanes. Simon recently
has shown that response to gemcitabine may be related
to the level of ribonucleotide reductase subunit 1 (RRM1),
and excision repair cross-complementing group 1 gene
(ERCC1) may predict response to platinum in patients
with lung cancer [31]. A BRCA1 mutation may similarly
predict response to different chemotherapy agents.
BRCA1 importance may be beyond its well-established
role with hereditary cancer. Given our understanding of
its functional role and clinical experience, BRCA1 status
potentially could be considered in the future as a marker
to help target effective chemotherapy.
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BRCA1 and taxanes
Neo-adjuvant chemotherapy means the use of
chemotherapy initially in patients with localized solid
tumours with the intent of increasing the potential for local
control by surgery and radiotherapy and delivering the
earliest possible treatment to micrometastatic disease [1].
This modality provides a unique opportunity to identify
molecular predictors of response to treatment in breast
cancer. Inclusion of taxanes in preoperative chemotherapy
improves pathologic response rates [2]. This may not be
the case in breast cancer patients with BRCA1 germline
mutations [3]. Therefore BRCA1 testing should be
considered for neo-adjuvant breast cancer chemotherapy
trials incorporating taxanes. Pilot studies could be started
in populations with founder mutations, e.g. Poland, where
BRCA1 testing can be done rapidly at a low price [4].
References
1. Frei E 3rd. What’s in a name – neoadjuvant. J Natl Cancer Inst
1988; 80: 1088-1089.
2. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA,
Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM,
Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes,
particularly weekly paclitaxel, in preoperative chemotherapy
improves pathologic complete response rate in estrogen receptor-
positive breast cancers. Ann Oncol 2007; 18: 874-880.
3. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M,
Stawicka M, Mierzwa T, Szwiec M, Wiœniowski R, Siolek M, Narod S,
Lubinski J. Response to neo-adjuvant chemotherapy in women
with BRCA1-positive breast cancers. Breast Cancer Res Treat 2007;
May 10 [Epub ahead of print].
4. Lubiñski J, Górski B, Huzarski T, Byrski T, Gronwald J, Serrano-
-Fernández P, Domaga³a W, Chosia M, Uciñski M, Grzybowska E,
Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J,
Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M,
Sorokin D, Wojnar A, Haus O, Sir J, Mierzwa T, Niepsuj S, Guga³a K,
GóŸdŸ S, Sygut J, Kozak-Klonowska B, Musiatowicz B, Posmyk M,
Kordek R, Morawiec M, Zambrano O, Waœko B, Fudali L, Skret J,
Surdyka D, Urbañski K, Mituœ J, Ryœ J, Szwiec M, Rozmiarek A,
Dziuba I, Wandzel P, Wiœniowski R, Szczylik C, Kozak A, Koz³owski W,
Narod SA. BRCA1-positive breast cancers in young women from
Poland. Breast Cancer Res Treat 2006; 99: 71-76.
Pax H.B. Willemse1, Rolf H. Sijmons2
1Department of Medical Oncology, University Medical
Centre Groningen, Groningen, the Netherlands
2Department of Genetics, University Medical Centre
Groningen, Groningen, the Netherlands
Testing breast cancer patients for BRCA1 mutations
is not necessarily a good step and various aspects
(medical, psychological, socio-legal) may make patients
decide for or against testing. If, however, knowing the
BRCA1 mutation status were important in choosing the
type of treatment, then a strong argument in favour of
testing would need to be discussed with these patients,
or, depending on the resources available, with only the
subset that have a significant chance of carrying a BRCA1
mutation.
Although in vitro studies of BRCA1-associated breast
cancers have demonstrated increased sensitivity to DNA-
damaging agents like mitomycin C and platinum, and
resistance to mitotic-spindle poisons, such as taxanes,
there is a paucity of clinical studies to support these
findings [reviewed in 1]. Byrski et al. have now reported
the response to neo-adjuvant chemotherapy of breast
cancer in a small retrospective study of BRCA1 mutation
carriers and matched controls. They observed a lower
response to taxane in the BRCA1 group compared with
controls. Together, these in vitro and clinical observations
suggest that the BRCA1 mutation carrier status could
be relevant to the choice of chemotherapeutic agents
in the treatment of breast cancer. However, larger and
prospective clinical studies are needed to explore this
issue more fully. At this time, outside research settings,
we would therefore not recommend BRCA1 mutation
analysis in breast cancer patients for the purpose of
choosing between the different chemotherapeutic agents
available.
Hereditary Cancer in Clinical Practice 2007; 5(3)142
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Taxane-based treatment of breast cancer patients in
neoadjuvant or adjuvant setting is still rare in Poland. 
The National Health Fund permits administration of
taxane-containing chemotherapy regimens in locally-
advanced breast cancer without providing additional
funds. In the Great Poland Cancer Centre in Poznan,
Poland, which is a main oncology centre in western Poland
(~1100 new breast cancer cases diagnosed each year),
taxane-based adjuvant regimens are not routinely
administrated. The standard chemotherapy regimens in
locally advanced breast cancer administered in our centre
are anthracycline-containing regimens – AC or FAC.
In the forthcoming months in the Great Poland
Cancer Centre we plan to introduce a routine evaluation
of BRCA1 gene status in all newly diagnosed breast
cancer patients prior to initiation of systemic treatment.
For a few years the National Health Fund has been
providing separate funds for treatment of metastatic
breast cancer patients with taxane-based chemotherapy.
Since there are significant numbers of patients receiving
such a systemic therapy, a routine evaluation of BRCA1
gene status prior to initiation of this treatment should be
considered. This procedure may identify patients who
would not benefit from the taxane-based chemotherapy
and for whom other cytotoxic drugs in a first-line treatment
would be potentially more effective.
Your proposal mainly focuses on patients with
locally-advanced breast cancer prior to initiation of 
a neoadjuvant systemic treatment. Despite the lack of
studies evaluating the influence of BRCA1 gene
mutations on the efficacy of adjuvant taxane-based
chemotherapy I think in the case of patients with 
a defective BRCA1 gene, administration of taxanes
following surgery should be restricted.
During the last decade several clinical trials
evaluating the efficacy of adjuvant taxanes in breast
cancer patients have been conducted. In many of the
trials Polish oncology centres were actively involved.
Patients enrolled in such studies must have a complete
pathological and clinical background and are very
tightly controlled during the treatment period and in
the follow-up. Therefore I think it may be worth
obtaining clinical data of breast cancer patients treated
in Poland with adjuvant taxanes in clinical studies and
make an effort to obtain patients’ biological samples
that will allow analysis of BRCA1 gene status. Based
on such information a reliable, retrospective clinical
analysis would be feasible.
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Opinion on article of the authors Byrski et al.:
Response to neo-adjuvant chemotherapy in women
with BRCA1-positive breast cancer
The article is very interesting and the results are
important. There are not many clinical data about the
effect of chemotherapy of patients with hereditary form
of breast and ovarian cancer induced by mutations in
the BRCA1 gene. The results of the study are in
agreement with pre-clinical data, which show that
chemotherapy based on taxanes has no importance
for breast cancers in BRCA1 mutation carriers.
Limitations:
• retrospective study, patient selection, possibility of
retroaction of the aims of the study on the basis of
results,
• case-control study with relatively low number of
patients (but in this diagnosis it is rather sizable),
• the search effect is debilitated by the many different
schemes of therapy,
• because of combination of anthracycline and taxane
it is not possible to expressly consider effect of taxanes.
Conclusion:
I evaluate the presented study as positive and the
results achieved are the basis for realization of 
a prospective study.
Zheng Shu
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Breast cancer is the main cancer of women
worldwide. Chemotherapy is one kind of the main
combination treatment. How to reasonably select 
a suitable high response regimen is an important issue
for the clinic. Neo-adjuvant chemotherapy may differ in
efficiency between hereditary BRCA1 mutation carriers
and a sporadic subgroup (non-carriers). Preclinical studies
have indicated that intact BRCA1 protein is required for
the desired cell response to taxol in cell lines.
Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers
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Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers
From this point of view, the authors speculated that
breast tumours that lack BRCA1 protein may be resistant
to taxane-based chemotherapies. They designed the
retrospective study with Poland registration data. A total
of 3,136 patients with patho-clinical record and blood
samples were collected. The blood was analyzed for
founder mutations in BRCA1. The 44 BRCA1 mutation
carrier cases received neo-adjuvant chemotherapy, and
there were 41 matched mutation-negative breast cancer
as control cases. The authors compared the different
regimens’ (CMF, CMFP, AC, FAC, and AT) response
between the BRCA1 mutation carriers and non-carriers,
comparing also between the two subgroups’ response
to the taxane-based regimen. The results are very
interesting and impressive as follows:
• the 15 BRCA1 mutation carriers were given docetaxel,
only 6 of 15 had a response (CR or PR); for comparison
12 of 12 non-carriers had complete or partial
response;
• all the remaining 29 BRCA1 mutation carries had a CR
or PR with other treatment regimens; they did not show
chemotherapy resistance during the neo-adjuvant
period.
In this study even though the number of the cases
is small, it really remained the clinician to design 
a further prospective study. Before the operation get
the blood to analyse the BRCA1 status and ER status
with core aspiration biopsy.
